Partnering with Takeda Oncology

Partnering with Takeda Oncology 

We complement our deep in-house expertise with a network of symbiotic partnerships to unlock the most promising science wherever it emerges 

Takeda Oncology seeks partnerships for novel, innovative, first-in-class and/or best-in-class discovery and clinical stage oncology opportunities that target indications / settings of unmet medical need and complement Takeda’s research expertise and commercial footprint, in particular in hematological malignancies and lung cancer. Takeda Oncology is open to considering clinical stage opportunities in other solid tumors which have high unmet medical need. 

Takeda’s discovery and early development efforts are focused on transformational approaches leveraging the innate immune system and Takeda continues to seek innovative technologies to augment these next generation platforms. Watch our Takeda Oncology Strategic Update  from June 2021 and read about how we’re pursuing cancer breakthroughs with novel immune-oncology approached in this article

If interested in partnering with Takeda Oncology, please reach out to our team at  

Learn more about partnering with Takeda.


To learn more about Oncology-specific Investor events and information, visit the Takeda Oncology Investor Relations page

Explore More


Keep up on the latest Oncology news by visiting our newsroom

Contact Takeda​

Contact global Takeda with general inquiries or send us a message

Oncology Pipeline

Discovering and developing innovative therapies to deliver potentially transformative treatments

Partnering with Takeda Oncology